ArticleCurrent microbiology2026
Antibacterial Potential of Patagonian Fungi: Screening, Metabolite Profiling, and Novel Findings.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patagonian fungi are an underexplored source of secondary metabolites with promising antimicrobial potential, a topic of growing relevance given the global spread of antibiotic resistance. In this study, we evaluated the antibacterial activity of 85 fungal isolates from Ascomycota, Basidiomycota, and Mucoromycota; 49 fungal conditioned media displayed inhibition against both Gram-positive and Gram-negative bacteria in a 96-well OD₆₀₀ microplate assay. Staphylococcus aureus, Bacillus subtilis, and Lysinibacillus sphaericus were the most sensitive Gram-positive strains, while Klebsiella pneumoniae showed the highest susceptibility among Gram-negative species. Complete inhibition of S. aureus was achieved in the conditioned-media assay by Arthrinium arundinis, Cladosporium sp., Graphilbum sp. 2, and Postia balsamea, with Graphilbum representing a previously unreported antimicrobial genus. In the conditioned-media microplate assay, potent antibacterial activity (> 99.5%) against all 5 tested bacterial strains was recorded for Allantophomopsis sp., Aureobasidium sp., Coniochaeta sp., Graphilbum sp. 2, and Mucor pyriformis, most of which have not been previously associated with antibacterial activity against Bacillus or Klebsiella genus. Marked inhibition of S. aureus and K. pneumoniae laboratory strains was observed for Arachnopeziza aurelia, Coprinellus sp., and Poria sp. Remarkably, Umbelopsis (Mucoromycota) inhibited all bacteria strains tested in the conditioned-media assay, revealing previously unreported antibacterial activity for this genus. Several extracts retained measurable but variable antibacterial activity in disk-diffusion assays producing inhibition zones against selected bacterial strains. Chemical profiling of active extracts revealed cyclic dipeptides (diketopiperazines) as recurrent metabolites and a unique family of unknown compounds exclusively found in Graphilbum sp. 2, representing its first metabolomic characterization. Overall, these results identify Patagonian fungi as a valuable reservoir of bioactive metabolites with potential as new natural antimicrobial agents.
Indexed as
Identifiers
42126595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.